Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2014

View Archived Issues

Kinetic analysis of the new PET ligand [11C]Lu-AE-92686

ProteoTech given FDA orphan drug status for AL amyloidosis candidate

RetroSense Therapeutics gene therapy gains FDA orphan drug status for retinitis pigmentosa

RadioMedix and Viewpoint Molecular Targeting receive grant for melanoma theranostics

iBio expands collaboration with Novici Biotech

Bavarian Nordic expands collaboration with Janssen on MVA-BN

GlaxoSmithKline reviews pipeline progress of third quarter 2014

VSV-ZEBOV Ebola vaccine candidate begins phase I study at NIAID

Serum bilirubin: a prognostic marker in primary sclerosing cholangitis

Phase III data from GEMINI trials presented for vedolizumab

First-in-human results presented for radiolabeled antibody [68Ga]ABY-025

Vitae Pharmaceuticals reports phase I results for BI-1181181/VTP-37948

The Walter Reed Army Institute discloses new agents for malaria

Novel GPR120 modulators divulged by Bristol-Myers Squibb

SHIELD 4 phase III data presented for vercirnon in patients with Crohn's disease

Sutro Biopharma and Celgene expand agreement for ADCs in immuno-oncology

U.S. group designs novel agents for depression and Parkinson's disease

Sumitomo Dainippon Pharma discloses novel RIO kinase 2 inhibitors

Bristol-Myers Squibb prepares novel agents for HIV infection

Stellar Biotechnologies agrees to supply KLH for BiovaxID

CTI BioPharma acquires worldwide rights to phase II cancer agent tosedostat

FDA sends CRL to Lundbeck regarding intravenous carbamazepine NDA

FDA approves Baxter's Obizur for acquired hemophilia A

CHMP adopts positive opinion for oxycodone/naloxone in RLS

CHMP recommends expanding approval of enzalutamide

EMA committee backs approval of olaparib in BRCA-mutated ovarian cancer

EMA recommends that Clinuvel's Scenesse be approved for EPP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...